![\"\"](\"https:\/\/i-base.info\/htb\/wp-content\/uploads\/2026\/02\/CROI-page-banner.png\")
<\/p>\n<\/p>\n
Simon Collins, HIV i-Base<\/strong><\/p>\n CROI 2026 included new results from the second stage of the RIO study using immune-based treatments in people who were diagnosed and treated in early HIV infection. [1]<\/strong><\/p>\n The two broadly neutralising antibodies (bNAbs) in RIO are 3BNC117 and 10-1074, and their impact on maintaining suppressed viral load was monitored after stopping HIV meds during one or more analytical treatment interruptions (ATI).<\/p>\n Last year at CROI, the results from Stage 1 of the randomised (1:1), double-blind placebo-controlled study were presented from 68 participants. [2]<\/p>\n This year, results were presented from 28 participants in Stage 2, including 7 in the placebo arm who had the chance to receive bNAbs after Stage 1 and 21 participants in the original active arm who had the choice to receive bNAbs a second time. This allowed for comparisons in viral load dynamics both (i) between groups and (ii) using paired comparisons within groups.<\/p>\n Median bNAb levels in the 7 Arm A participants were similar at the beginning of Stage 2 at <50 ug\/mL to when viral load rebounded in Stage 1 (i.e. below the threshold level for effect).<\/p>\n Results overall showed that participants were much less likely to rebound in ATI 2 compared to ATI 1 (50% vs 100%) with HR 0.17 (95%CI 0.08 to 0.35) p<0.0001, and with many maintaining low-level viraemia rather than rapidly rebounding.<\/p>\n The median viral load peak was also significantly lower (p=0.0003) and the viral load doubling time was significantly slower (p=0.006) after ATI 2 compared to after ATI 1, although some participants had other responses.<\/p>\n ATI 2 generated either early viral load responses within 9 weeks or slower drawn out responses over 48 weeks and longer. Although there were no differences between early viral load responses after ATI 2 compared to ATI 1, there were significant differences in participants with slower viral load rebound with lower viral load peaks (p<0.001) and slower doubling time (p=0.011).<\/p>\n The ongoing Arm C of the RIO study is looking further at the dynamics of viral rebound and responses in relation to timing of ATI and bNAbs in a new cohort of 18 participants.<\/p>\n Both bNAbs in RIO were produced at Rockefeller University and are now in development at Gilead.<\/p>\n Note: Simon Collins is a community representative on the RIO study.<\/p>\n References<\/p>\n Simon Collins, HIV i-Base CROI 2026 included new results from the second stage of the RIO study using immune-based treatments in people who were diagnosed and treated in early HIV infection. [1] The two broadly neutralising antibodies (bNAbs) in RIO …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[163,4,20],"tags":[346],"class_list":["post-53678","post","type-post","status-publish","format-standard","hentry","category-early-access","category-conference-reports","category-cure-research","tag-croi-2026"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53678","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=53678"}],"version-history":[{"count":10,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53678\/revisions"}],"predecessor-version":[{"id":53693,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/53678\/revisions\/53693"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=53678"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=53678"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=53678"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\nhttps:\/\/www.croiconference.org\/abstract\/1206-2026<\/a> (abstract)
\nhttps:\/\/www.croiwebcasts.org\/console\/player\/55099<\/a> (webcast)<\/li>\n
\nhttps:\/\/i-base.info\/htb\/50530<\/a><\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"